Nelfinavir
- Generic Name
- Nelfinavir
- Brand Names
- Viracept
- Drug Type
- Small Molecule
- Chemical Formula
- C32H45N3O4S
- CAS Number
- 159989-64-7
- Unique Ingredient Identifier
- HO3OGH5D7I
- Background
Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
- Indication
Used in combination with other antiviral drugs in the treatment of HIV in both adults and children.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT04169763
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Registration Number
- NCT03422874
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix
- Conditions
- Interventions
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Tata Memorial Hospital
- Target Recruit Count
- 348
- Registration Number
- NCT03256916
- Locations
- 🇮🇳
Tata Memorial Centre, Mumbai, Maharashtra, India
A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)
- First Posted Date
- 2015-02-16
- Last Posted Date
- 2020-04-06
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 6
- Registration Number
- NCT02363829
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Effect of Different Boosting Agents on Pharmacokinetics of BILR 355 BS Dissolved in Polyethylene Glycol 400 (PEG 400) in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 44
- Registration Number
- NCT02257008
Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 34
- Registration Number
- NCT02188537
- Locations
- 🇨🇭
Universitaetsspital-Basel, Basel, Switzerland
🇨🇭Istituto Oncologico Svizzera Italiana IOSI, Bellinzona, Switzerland
🇨🇭Hopital Fribourgeois, Fribourg, Switzerland
Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors
- Conditions
- Interventions
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2016-06-10
- Target Recruit Count
- 1
- Registration Number
- NCT02080416
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Nelfinavir in Systemic Lupus Erythematosus
- First Posted Date
- 2014-02-19
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 15
- Registration Number
- NCT02066311
- Locations
- 🇺🇸
Hospital for Special Surgery, New York, New York, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸New York University School of Medicine, New York, New York, United States
Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 159
- Registration Number
- NCT02024009
- Locations
- 🇬🇧
University Hospitals Coventry and Warwickshire NHS Trust, University Hospital Coventry, Coventry, United Kingdom
🇬🇧Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, United Kingdom
🇬🇧East Suffolk and North Essex NHS Foundation Trust, Colchester District General Hospital, Colchester, United Kingdom
A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.